Brief: AnaptysBio Q4 Net Income USD -21.784 Million
27/02/2025 21:15
Feb 27 (Reuters) - AnaptysBio Q4 operating expenses USD 52.783 million. Q4 income from operations USD -9.67 million Q4 collaboration revenue USD 43.113 million
Recent news on AnaptysBio
See all newsFirst Tracks Biotherapeutics up after $200 mln equity raise
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Brief: Anaptys Announces Second Quarter And Transitional Fiscal Year 2026 Financial Results And Provides Business Update
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties